News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Annual General Meeting of MagForce Nanotechnologies


8/7/2013 9:36:36 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

BERLIN, GERMANY--(Marketwired - August 07, 2013) - MagForce AG /Annual General Meeting of MagForce AG.

Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.

The issuer is solely responsible for the content of this announcement.

* Annual General Meeting approves agenda with a clear majority

* Executive Board and Supervisory Board have been discharged

* Outlook for the 2013 fiscal year confirmed

MagForce AG (Frankfurt, Entry Standard, XETRA:MF6), a leading medical device company in the field of nanomedicine focused on oncology, held its annual general meeting yesterday, August 6, 2013, in Berlin. The annual general meeting approved all of the items on the agenda with a clear majority and granted discharge to the Executive and Supervisory Boards for the 2012 fiscal year. The Executive Board members Prof. Dr. Hoda Tawfik and Christian von Volkmann provided a status update regarding current operational developments, an overview of the 2012 fiscal year and the outlook for the current year. The Executive and Supervisory Boards were pleased with the outcome of the resolutions.

The Executive Board's presentation is available from the company's website at www.magforce.de/presse-investoren/hauptversammlung (German only).

About MagForce AG

MagForce AG is a leading medical device company in the field of nanomedicine in oncology. The Company's proprietary, NanoTherm(®) therapy, enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. NanoTherm(®), NanoPlan(®), and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm(®), NanoPlan(®), and NanoActivator™ are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.


Disclaimer

This release may contain forward-looking statements and information which may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates" or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.

MagForce_Press Release_August 7, 2013: http://hugin.info/143761/R/1721783/573503.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MagForce AG via Thomson Reuters ONE

[HUG#1721783]


For further information:
Anne Hennecke
MC Services AG
Email Contact
P +49 89 210 228 18
F +49 89 210 228 88
M +49 151 12 555 759



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES